Jake E Thistle1, Ylva Hellberg2, Kristina Mortensen2, Stephen Hamilton-Dutoit2, Anders Kjærsgaard3, Deirdre Cronin-Fenton3, Henrik Toft Sørensen3, Timothy L Lash4,5. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 2. Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. 3. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. tlash@emory.edu. 5. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. tlash@emory.edu.
Abstract
PURPOSE: Overexpression of 14-3-3ζ has been linked to breast cancer recurrence in several studies, including studies assessing its effect on tamoxifen resistance. The study was performed to estimate the effect of 14-3-3ζ and differentiate potential prognostic or predictive utility. METHODS: A case-control study, nested in a population of 11,251 females residing on the Jutland Peninsula of Denmark, was performed. Participants were aged 35-69, diagnosed with stage I, II, or III breast cancer between 1985 and 2001, and registered with the Danish Breast Cancer Cooperative Group. We identified 541 recurrent breast cancer cases with estrogen receptor-positive disease treated with tamoxifen for at least 1 year (ER+/TAM+) and 300 cases with estrogen receptor-negative disease never treated with tamoxifen (ER-/TAM-). We matched cases to controls on ER/TAM status, date of surgery, menopausal status, stage, and county. 14-3-3ζ expression was assessed using immunohistochemistry on tissue microarrays. We computed the odds ratio (OR) associating 14-3-3ζ expression with breast cancer recurrence adjusting for confounding using logistic regression. A quantitative bias analysis was performed to account for bias due to expression assay methods. RESULTS: Associations for cytoplasmic and nuclear 14-3-3ζ staining above the 50th percentile were near null in both ER+/TAM+ and ER-/TAM- patients. When examining combined 14-3-3ζ staining, the association increased in the ER+/TAM+ group (adjusted OR 1.44, 95% confidence interval (CI) 1.05, 1.99). A nearly twofold increase in odds of recurrence was observed in above the 75th percentile staining of combined 14-3-3ζ, both for ER+/TAM+ patients (adjusted OR 1.93, 95% CI 1.15, 3.24) and ER-/TAM- patients (adjusted OR 1.93, 95% CI 1.03, 3.62), indicating potential prognostic utility. CONCLUSION: Evidence is lacking to conclude that 14-3-3ζ is a useful marker of tamoxifen resistance; however, 14-3-3ζ expression is a potentially useful prognostic marker of breast cancer recurrence. Independent utility beyond established prognostic markers needs to be determined.
PURPOSE: Overexpression of 14-3-3ζ has been linked to breast cancer recurrence in several studies, including studies assessing its effect on tamoxifen resistance. The study was performed to estimate the effect of 14-3-3ζ and differentiate potential prognostic or predictive utility. METHODS: A case-control study, nested in a population of 11,251 females residing on the Jutland Peninsula of Denmark, was performed. Participants were aged 35-69, diagnosed with stage I, II, or III breast cancer between 1985 and 2001, and registered with the Danish Breast Cancer Cooperative Group. We identified 541 recurrent breast cancer cases with estrogen receptor-positive disease treated with tamoxifen for at least 1 year (ER+/TAM+) and 300 cases with estrogen receptor-negative disease never treated with tamoxifen (ER-/TAM-). We matched cases to controls on ER/TAM status, date of surgery, menopausal status, stage, and county. 14-3-3ζ expression was assessed using immunohistochemistry on tissue microarrays. We computed the odds ratio (OR) associating 14-3-3ζ expression with breast cancer recurrence adjusting for confounding using logistic regression. A quantitative bias analysis was performed to account for bias due to expression assay methods. RESULTS: Associations for cytoplasmic and nuclear 14-3-3ζ staining above the 50th percentile were near null in both ER+/TAM+ and ER-/TAM- patients. When examining combined 14-3-3ζ staining, the association increased in the ER+/TAM+ group (adjusted OR 1.44, 95% confidence interval (CI) 1.05, 1.99). A nearly twofold increase in odds of recurrence was observed in above the 75th percentile staining of combined 14-3-3ζ, both for ER+/TAM+ patients (adjusted OR 1.93, 95% CI 1.15, 3.24) and ER-/TAM- patients (adjusted OR 1.93, 95% CI 1.03, 3.62), indicating potential prognostic utility. CONCLUSION: Evidence is lacking to conclude that 14-3-3ζ is a useful marker of tamoxifen resistance; however, 14-3-3ζ expression is a potentially useful prognostic marker of breast cancer recurrence. Independent utility beyond established prognostic markers needs to be determined.
Entities:
Keywords:
14-3-3ζ; Breast cancer recurrence; Predictive marker; Prognostic marker; Tamoxifen
Authors: D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn Journal: J Natl Cancer Inst Date: 1996-10-16 Impact factor: 13.506
Authors: Anna Bergamaschi; Jonna Frasor; Kristina Borgen; Adina Stanculescu; Patricia Johnson; Kendrith Rowland; Elizabeth L Wiley; Benita S Katzenellenbogen Journal: Breast Cancer Res Treat Date: 2012-12-28 Impact factor: 4.872
Authors: Victor R Grann; Andrea B Troxel; Naseem J Zojwalla; Judith S Jacobson; Dawn Hershman; Alfred I Neugut Journal: Cancer Date: 2005-06-01 Impact factor: 6.860
Authors: S Gruvberger; M Ringnér; Y Chen; S Panavally; L H Saal; M Fernö; C Peterson; P S Meltzer Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701
Authors: Jonna Frasor; Edmund C Chang; Barry Komm; Chin-Yo Lin; Vinsensius B Vega; Edison T Liu; Lance D Miller; Johanna Smeds; Jonas Bergh; Benita S Katzenellenbogen Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: Christopher L Neal; Jun Yao; Wentao Yang; Xiaoyan Zhou; Nina T Nguyen; Jing Lu; Christopher G Danes; Hua Guo; Keng-Hsueh Lan; Joe Ensor; Walter Hittelman; Mien-Chie Hung; Dihua Yu Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Cathrine F Hjorth; Anja S Nielsen; Henrik T Sørensen; Timothy L Lash; Per Damkier; Stephen Hamilton-Dutoit; Deirdre Cronin-Fenton Journal: Acta Oncol Date: 2018-11-20 Impact factor: 4.089
Authors: Maiquidieli Dal Berto; Giovana Tavares Dos Santos; Aniúsca Vieira Dos Santos; Andrew Oliveira Silva; José Eduardo Vargas; Rafael José Vargas Alves; Fernanda Barbisan; Ivana Beatrice Mânica da Cruz; Claudia Giuliano Bica Journal: Discov Oncol Date: 2021-10-01